title: Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study.
abstract: BACKGROUND
  This trial investigated the activity and toxicity of gemcitabine in previously untreated elderly (> 70 years) patients with advanced (stage IIIB-IV) non-small cell lung cancer (NSCLC).
  
  
  METHODS
  From January 1997 to July 1998, 46 patients with advanced NSCLC aged over 70 years with a performance status of 0-2 were entered into the study. Gemcitabine 1000 mg/m2 was administered as a 30-min infusion once a week for 3 weeks followed by a week of rest; cycles were repeated every 4 weeks.
  
  
  RESULTS
  Forty-four patients were evaluable for response. One complete response and nine partial responses were observed, for an overall response rate of 22.2% (95% C.I.: 11.3-37.5). The median time to disease progression was 5.1 months (95% C.I.: 3.5-6.7), the median duration of response was 6.3 months, and the median overall survival time 6.75 months (95% C.I.: 5.3-8.2). All patients were evaluable for toxicity (184 cycles, median = 3 cycles/patient) and no grade 4 hematologic toxicities were reported. WHO grade 3 leukopenia, neutropenia and anemia occurred in 3.3, 0.5 and 1.1% of cycles, respectively. Grade 3 skin rash occurred in 4.3% of patients. These side effects led to treatment discontinuation in two patients.
  
  
  CONCLUSIONS
  Our data show that gemcitabine is active and well tolerated in patients aged over 70 years with advanced NSCLC.
authors.affiliation: Department of Oncology, S. Chiara Hospital and University, Pisa, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Ricci
authors.forename: A
authors.initials: A
authors.lastname: Antonuzzo
authors.forename: L
authors.initials: L
authors.lastname: Galli
authors.forename: C
authors.initials: C
authors.lastname: Tibaldi
authors.forename: M
authors.initials: M
authors.lastname: Bertuccelli
authors.forename: A
authors.initials: A
authors.lastname: Lopes Pegna
authors.forename: S
authors.initials: S
authors.lastname: Petruzzelli
authors.forename: R
authors.initials: R
authors.lastname: Algeri
authors.forename: V
authors.initials: V
authors.lastname: Bonifazi
authors.forename: M L
authors.initials: ML
authors.lastname: Fioretto
authors.forename: C
authors.initials: C
authors.lastname: Orlandini
authors.forename: P F
authors.initials: PF
authors.lastname: Conte
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine